Clik here to view.
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet...
Monday, December 12th 2016 at 6:00am UTC No benefit observed upon addition of Fovista® to monthly Lucentis® regimen for the treatment of wet age-related macular degeneration – Conference Call and...
View ArticleClik here to view.
Global Hypereosinophilic Syndrome Therapeutics Pipeline Review 2016 –...
Monday, December 12th 2016 at 2:30pm UTC DUBLIN–(BUSINESS WIRE)– Research and Markets has announced the addition of the « Hypereosinophilic Syndrome – Pipeline Review, H2 2016″ report to their...
View ArticleClik here to view.
Pfizer Declares First-Quarter 2017 Dividend
Monday, December 12th 2016 at 4:53pm UTC Board of Directors approves increase in quarterly cash dividend to $0.32 per share NEW YORK–(BUSINESS WIRE)– The board of directors of Pfizer Inc. today...
View ArticleClik here to view.
Lumendi Receives FDA Clearance to Market DiLumen™ for Endolumenal Therapy
Tuesday, December 13th 2016 at 11:00am UTC New Endolumenal Interventional Platform Developed by Lumendi with Digestive Disease Leaders at New York-Presbyterian and Weill Cornell Medicine’s MINT...
View ArticleClik here to view.
Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S....
Tuesday, December 13th 2016 at 2:30pm UTC NEW YORK–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) today announced important changes to its U.S. geographic footprint that will strengthen...
View ArticleClik here to view.
Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of...
Wednesday, December 14th 2016 at 9:15pm UTC NEW YORK & TOKYO–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503) today announced the Phase 4 PLATO study, evaluating the...
View ArticleClik here to view.
Siemens Healthineers to Significantly Expand Its Walpole, Mass. Laboratory...
Wednesday, December 14th 2016 at 11:00am UTC Siemens will invest $300M in Walpole, Mass. laboratory diagnostics manufacturing facility over the next four years Facility will manufacture assays for the...
View ArticleClik here to view.
Axiom Announces Agreement with Johnson & Johnson Services, Inc. to Provide...
Thursday, December 15th 2016 at 2:00pm UTC NEW YORK–(BUSINESS WIRE)– Axiom, a leading provider of technology-enabled legal and contracting services, today announced a 5-year, managed contracting...
View ArticleClik here to view.
BIO CEO & Investor Conference Programming Announced
Thursday, December 15th 2016 at 4:14pm UTC February 13-14 Meeting to Feature Fireside Chats with Bristol-Myers Squibb CEO, Giovanni Caforio and Yumanity Therapeutics CEO, Tony Coles...
View ArticleClik here to view.
Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous...
Thursday, December 15th 2016 at 10:00pm UTC NEW YORK–(BUSINESS WIRE)– Regulatory News: Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies...
View ArticleClik here to view.
Cellectis Announces Conference Call To Discuss Recent Recombinant DNA...
Friday, December 16th 2016 at 10:13pm UTC NEW YORK–(BUSINESS WIRE)– Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on...
View ArticleClik here to view.
Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam...
Friday, December 16th 2016 at 12:00pm UTC – Three Mid- to Late-Stage Programs Advancing Toward Potential Commercialization – – In Addition, Company Announces Positive Preliminary Results fromPhase 1...
View ArticleClik here to view.
FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric...
Friday, December 16th 2016 at 7:09pm UTC Labeling Revisions Also Include Updates to Corresponding Warning and Addition of Clinical Data on Superior Efficacy of CHANTIX Compared to Bupropion or...
View ArticleClik here to view.
FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE®...
Wednesday, December 21st 2016 at 1:00pm UTC sNDA includes data from Phase 3 PALOMA-2 trial to support conversion from accelerated approval to regular approval NEW YORK–(BUSINESS WIRE)– Pfizer Inc....
View ArticleClik here to view.
Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
Wednesday, December 21st 2016 at 1:30pm UTC Caforio will Succeed Lamberto Andreotti Effective May 2, 2017 NEW YORK–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) today announced that the...
View ArticleClik here to view.
22nd Century Group Announces Major Scientific Collaboration with University...
Tuesday, December 20th 2016 at 2:50pm UTC 22nd Century granted exclusive rights to commercialize Industrial Hemp Plants and Medically Important Cannabinoids that result from the alliance. CLARENCE,...
View ArticleClik here to view.
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus...
Tuesday, December 20th 2016 at 11:59am UTC NEW YORK & OXFORD, United Kingdom–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an...
View ArticleClik here to view.
CLEAR Adds to Experienced Leadership Team to Support Major Nationwide Expansion
Wednesday, December 21st 2016 at 2:30pm UTC Biometric Platform Already Serving More Than 700,000 Members Brings on Executives from U.S. Customs Service, Amazon, American Express & Avon NEW...
View ArticleClik here to view.
Bristol-Myers Squibb and Calithera Biosciences Announce Clinical...
Wednesday, December 21st 2016 at 11:59am UTC Study to evaluate potential of CB-839 plus Opdivo to target immune-suppressive cells in the tumor microenvironment NEW YORK & SOUTH SAN FRANCISCO,...
View ArticleClik here to view.
Inogen to Participate in Upcoming Investor Conferences
Wednesday, December 21st 2016 at 9:01pm UTC GOLETA, Calif.–(BUSINESS WIRE)– Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare...
View Article